Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types

Feng Wang; Qi Zhao; Ying-Nan Wang; Ying Jin; Ming-Ming He; Ze-Xian Liu; Rui-Hua Xu

doi:10.1001/jamaoncol.2019.2963

Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types

JAMA Oncol. 2019 Oct 1;5(10):1504-1506. doi: 10.1001/jamaoncol.2019.2963.

Authors

Feng Wang¹, Qi Zhao¹, Ying-Nan Wang¹, Ying Jin¹, Ming-Ming He¹, Ze-Xian Liu¹, Rui-Hua Xu¹

Affiliation

¹ State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

Abstract

This cohort study analyzes the medical records of 47 721 patients with various cancer types with POLE/POLD1 mutations to evaluate whether the mutations were associated with immunotherapy outcomes.